Pharma and Pharmaceutical - Pharma Rep Focus

Why hasn’t pharma embraced email marketing?

World of DTC Marketing

MARCH 9, 2021

eMail represents an opportunity for pharmaceutical companies to get closer to their customers while increasing adherence and compliance. Pharma has an opportunity to engage customers and caregivers via email but they can’t send out product flyers. The other challenge for pharma in an email marketing campaign is privacy.

Marketing

Marketing Pharma Prospecting Education

Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs

Fierce Pharma

NOVEMBER 5, 2024

With its first FDA approval coming in August and a sec | With its first FDA approval coming in August and a second expected next month, these are exhilarating days for 19-year-old Syndax Pharmaceuticals as it transforms into a commercial enterprise.

Pharma

Pharma FDA Pharmaceutical

How did pharma develop a vaccine so quickly?

World of DTC Marketing

DECEMBER 29, 2020

A key consideration is funding – public and private cash has been poured into the race for a Covid vaccine, pushing aside the usual financial concerns facing pharmaceutical companies. Let’s also remember that pharma is going to make a LOT of money on these vaccines. The post How did pharma develop a vaccine so quickly?

Pharma

Pharma Food and Drug Administration Media Food

IFF, after brief leadership stint under Merck's Frank Clyburn, pawns off pharma solutions business for $2.85B

Fierce Pharma

MARCH 19, 2024

New York's IFF—which dabbles in food, beverage, beauty and pharmaceutical supply chains, among others—has agreed to sell its pharma solutions business to French plant-based ingredient maker Roquette for up to $2.85 After a two-year stint under Merck & Co.

Pharma

Pharma Food Healthcare Healthcare

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

OCTOBER 5, 2021

drug pricing system is filled with confusing numbers , and many entities profit off the flow of drugs, but pharmaceutical companies retain a vast majority of the proceeds” Big pharma IS big business. Big Pharma’s chokehold around the U.S. Via Axios “The 10 highest-selling drugs in the U.S. So what’s your point?

Pharma

Pharma Insurance Sales Government

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Fierce Pharma

JANUARY 20, 2023

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban fkansteiner Fri, 01/20/2023 - 15:34

Pharmaceutical

Ferring inks $500M deal with Royalty Pharma on new bladder cancer gene therapy

Fierce Pharma

AUGUST 24, 2023

Royalty Pharma has built a niche by finding innovative products pre- and post-approval from companies that need an infusion of cash in exchange for future royalties. Royalty Pharma has signed a deal with Ferring Pharmaceuticals to collect royalties on bladder cancer drug Adstiladrin.

Pharma

Pharma Manufacturing Sales Pharmaceutical

At long last, AstraZeneca, Pfizer, J&J, Roche and others have an ally in Biden

Fierce Pharma

MAY 23, 2024

Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma drug pricing, the industry has rarely seen good news coming from the White House.

Pharma

Pharma Medical Pharmaceutical

Scilex's Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect

Fierce Pharma

SEPTEMBER 3, 2024

Semnur Pharmaceuticals, which is working on a non-opioid prospect for sciatica, has agreed to merge with special purpose acquisition company Denali Capital Acquisition Corp. Semnur Pharmaceuticals is following in its parent company Scilex's footsteps with a special purpose acquisition company (SPAC) merger.

Prospecting

Prospecting Pharmaceutical Specialization

The current pharma business model is unsustainable

World of DTC Marketing

SEPTEMBER 7, 2022

Wall Street wants growth, as do investors, but that may be impossible for pharmaceutical companies. In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharma companies.

Pharma

Pharma Food and Drug Administration Marketing Prescription

ARS Pharmaceuticals hit with surprise FDA rejection of Neffy, its nasal spray epinephrine alternative

Fierce Pharma

SEPTEMBER 20, 2023

ARS Pharmaceuticals learned that lesson the hard way, as the FDA issued a surprise rejection of its anaphylaxis nasal spray Neffy. Positive FDA advisory committee votes aren’t always a blueprint for approval. Positive FDA advisory committee votes aren’t always a blueprint for approval.

FDA

FDA Pharmaceutical

Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case

Fierce Pharma

OCTOBER 7, 2024

Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said. With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S.

Pharma

Pharma Pharmaceutical

Discover Breakthrough Pharma Marketing Strategies at Digital Pharma East 2024

Fierce Pharma

AUGUST 5, 2024

The pharmaceutical industry is in a constant state of evolution, driven by technological advancements, shifting consumer behaviors, and a complex regulatory landscape. Join us at Digital Pharma East 2024 on Sept. 9-12 in Philadelphia to learn, connect, and innovate with your life sciences marketing industry peers.

Pharma

Pharma Marketing Pharmaceutical

FDA rejects Defender Pharma's motion sickness nasal gel candidate

Fierce Pharma

JANUARY 30, 2024

regulator has sent a complete response letter to Defender Pharmaceuticals, rejecting DPI-396 for the prevention of nausea and vomiting induced by motion. . | A nasal gel version of the motion sickness drug scopolamine has failed to make the grade with the FDA.

FDA

FDA Pharma Pharmaceutical

AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players

Fierce Pharma

NOVEMBER 22, 2023

In a lawsuit filed in Delaware federal court Monday, AbbVie accused Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals and Sun Pharmaceutical of trying to sidestep dozens of patents protecting Rinvoq through the next decade.

Pharmaceutical

Pharmaceutical Pharma Marketing

Delaware's Marlex Pharmaceuticals recalls 2 batches of heart failure drug after labeling mix-up

Fierce Pharma

SEPTEMBER 1, 2023

Marlex Pharmaceuticals of New Castle, Delaware, is recalling two lots of digoxin tablets at the 0.125-mg and 0.25-mg When it comes to heart failure medication, a labeling mix-up can have dire consequences. mg dose, and vice versa.

Pharmaceutical

Pharmaceutical Medical

Supreme Court blocks Purdue Pharma's bankruptcy settlement, threatening immunity to Sackler family

Fierce Pharma

AUGUST 11, 2023

It’s been a rough summer for pharmaceutical companies trying to resolve lawsuits by declaring bankruptcy. | The Supreme Court has halted Purdue Pharma’s $6-billion bankruptcy settlement, which granted the company’s former owners—the Sackler family—immunity from civil suits related to the opioid crisis.

Pharma

Pharma Pharmaceutical

Vanda, despite FDA rejection, swats down another buyout bid from Cycle

Fierce Pharma

OCTOBER 14, 2024

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based based company. | based company.

FDA

FDA Pharmaceutical Pharma

Pharma group blasts UK's drug rebate scheme shortly after lauding 'landmark' spending deal

Fierce Pharma

DECEMBER 5, 2023

Despite what was presented as a “landmark” deal between the pharmaceutical companies and the government, the U.K.’s s pharma association has not stopped pressuring the government for more industry-fr | Despite what was presented as a “landmark” deal between the pharmaceutical companies and the government, the U.K.’s

Pharma

Pharma Government Pharmaceutical

The 2025 Pharma Toolkit for Virtual Medical Education

Impetus Digital

DECEMBER 23, 2024

Pharma-exclusive Webinar: The 2025 Pharma Toolkit for Virtual Medical Education About the webinar Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders.

Education

Education Medical Pharma Training

How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B

Fierce Pharma

AUGUST 15, 2023

billion buyout of Skyclarys-maker Reata Pharmaceuticals surprised some industry watchers last month. billion buyout of Skyclarys-maker Reata Pharmaceuticals surprised some industry watchers last month. Biogen’s $7.3 Biogen’s $7.3

Pharma

Pharma Pharmaceutical

As ICER places a spotlight on pharma's price hikes, J&J, Roche and more hit back

Fierce Pharma

DECEMBER 11, 2023

After many years of tracking the pharmaceutical industry’s pricing tactics, the Institute for Clinical and Economic Review (ICER) is once again placing a spotlight on the price increases that end u | The Institute for Clinical and Economic Review (ICER)’s fifth annual report on unsupported price increases (UPI) puts Humira in the top spot of offenders. (..)

Pharma

Pharma Pharmaceutical

Apellis parries Astellas' long-term Izervay data with 3-year results on its rival GA med Syfovre

Fierce Pharma

NOVEMBER 6, 2023

billion buyout by Japanese pharma Astellas—the battle for the geographic atrophy (GA) crown is on in the | After this summer’s approval of Iveric Bio’s Izervay—the drug at the center of the $5.9 billion buyout by Japanese pharma Astellas—the battle for the geographic atrophy crown is on in the U.S.

Pharma

Pharma FDA Pharmaceutical

'The Top Line': Breaking down Eli Lilly’s ESG formula

Fierce Pharma

FEBRUARY 23, 2024

This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry. | This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry.

Government

Government Pharmaceutical Pharma

Addressing the evolving needs of pharma for CDx development

Fierce Pharma

DECEMBER 19, 2023

Agilent Technologies discusses the importance of working with pharmaceutical companies to drive medical innovation and improve patient outcomes, helping to speed up the process of bringing the right treatments to the right patients at the right time. Partnerships in healthcare have never been more important.

Pharma

Pharma Healthcare Healthcare Medical

Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

Fierce Pharma

MARCH 28, 2024

[Yangzhou, China - March 26, 2024] - Aurisco Pharmaceutical, a leading global pharmaceutical company, is excited to announce the completion of its investment in cGMP peptide manufacturing capacity | Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

Manufacturing

Manufacturing Pharmaceutical Leads

Fierce Pharma Asia—Ono buys Deciphera for $2.4B; Novartis expands PeptiDream collab; WuXi Bio exits BIO 2024

Fierce Pharma

MAY 2, 2024

Japan's Ono Pharmaceutical will buy kinase inhibitor expert Deciphera for $2.4 Novartis invests further in radiopharmaceuticals with two deals. Japan's Ono will buy kinase inhibitor expert Deciphera for $2.4 Novartis invests further in radiopharmaceuticals with two deals. grows hostile against certain Chinese biotech companies.

Pharma

Pharma Pharmaceutical

Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis

MedCity News

SEPTEMBER 24, 2024

Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas. The post Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis appeared first on MedCity News.

Pharma

Pharma Pharmaceutical Medical Biopharma

Eton Pharma hit with FDA rejection for methanol poison treatment as regulator flags manufacturing concerns

Fierce Pharma

JUNE 28, 2023

Eton Pharmaceuticals’ dehydrated alcohol injection didn’t pass muster with the FDA, instead receiving a complete response letter (CRL) raising flags the company believes are “addressable.” | The dehydrated alcohol injection was turned down due to problems with its chemistry manufacturing and controls, issues which the company believes are addressable, (..)

Manufacturing

Manufacturing FDA Pharma Pharmaceutical

Woes mount for Marinus with investor lawsuit, trial failure

Fierce Pharma

JUNE 17, 2024

The failure of Marinus Pharmaceuticals’ trial for ganaxolone as a treatment for persistent seizures has left the Philadelphia company facing the daunting prospect of conducting a new study to | The failure of Marinus Pharma’ trial for ganaxolone as a treatment for persisting seizures has left the Philadelphia company facing the daunting prospect of (..)

Prospecting

Prospecting Pharma Pharmaceutical

Pfizer moves to settle more than 10,000 Zantac cases in state courts: Bloomberg

Fierce Pharma

MAY 8, 2024

Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of heartburn drug Zantac, resolving litigation in several U. state courts, according to Bloomberg.

Leads

Leads Pharmaceutical

Harnessing data powers marketing programs to enable precise targeting

Fierce Pharma

OCTOBER 5, 2023

This discussion interviews Harshit Jain, a physician turned entrepreneur and founder of Doceree, a company solving healthcare professional marketing challenges focused on pharmaceuticals. |

Marketing

Marketing Physicians Pharma Healthcare

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M

MedCity News

NOVEMBER 6, 2024

Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The post Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M appeared first on MedCity News.

FDA

FDA Pharma Pharmaceutical Biopharma

Pharma Horizons: Biologics

European Pharmaceutical Review

SEPTEMBER 25, 2024

This report delves into the latest developments impacting the pharmaceutical biologic drug sector today. The post Pharma Horizons: Biologics appeared first on European Pharmaceutical Review. Inside, articles explore current key topics including biosimilars, antibody drugs, manufacturing, drug delivery and vaccines.

Pharma

Pharma Manufacturing Pharmaceutical Patients

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency

MedCity News

AUGUST 12, 2024

FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. The post Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency appeared first on MedCity News.

FDA

FDA Pharma Competition Pharmaceutical

Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition

MedCity News

OCTOBER 14, 2024

Lundbeck says Longboard Pharmaceuticals’ drug, bexicaserin, has potential applications in a range of rare epilepsies. Longboard Pharma Acquisition appeared first on MedCity News. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome.

Pharma

Pharma Pharmaceutical Biopharma

How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come

MedCity News

OCTOBER 20, 2024

Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News.

Pharma

Pharma Leads Pharmaceutical Biopharma

Lilly, AbbVie, BMS and more rally against UK's 'arbitrary' growth cap on branded drug market

Fierce Pharma

OCTOBER 17, 2023

Even as pharma giants try to get a handle on the Inflation Reduction Act in the U.S., working to tweak the Statutory Scheme for branded medicines, the Association of the British Pharmaceutical Industry is making its discontent known—and it’s managed to rally more than 20 major drugmakers to its cause. With the U.K.

Marketing

Marketing Medicine Pharma Management

In launching epinephrine nasal spray, ARS Pharma has a 'blue sky opportunity,' analyst says

Fierce Pharma

AUGUST 21, 2024

Gaining FDA approval for its epinephrine nasal spray came nearly a year later than expected for ARS Pharmaceuticals. Gaining FDA approval for its epinephrine nasal spray came nearly a year later than expected for ARS Pharmaceuticals.

FDA

FDA Pharma Pharmaceutical

After Xiidra deal with Bausch, Novartis divests Indian eye care brands to J.B. Pharma for $116M

Fierce Pharma

DECEMBER 20, 2023

Chemicals & Pharmaceuticals. Last year, reports surfaced that Novartis—hot off the heels of a planned restructuring and spinoff of generics giant Sandoz—was further weighing a sale for its ophthalmology business. | In a deal worth around $116 million, Novartis is handing over a portfolio of “select ophthalmology brands” to Mumbai’s J.B.

Distribution

Distribution Sales Pharma Medicine

It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash

Fierce Pharma

OCTOBER 31, 2024

Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potentia | Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potential blockbuster Rezdiffra.

Sales

Sales Pharmaceutical Marketing

Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease

Fierce Pharma

OCTOBER 28, 2024

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy.

Pharmaceutical

Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study

MedCity News

SEPTEMBER 9, 2024

The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News.

Leads

Leads Pharma Pharmaceutical Medical

Amneal agrees to $272.5M settlement to resolve opioid lawsuits

Fierce Pharma

MAY 6, 2024

Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and Native American jurisdictions claiming that the New Jersey generics producer | Amneal Pharmaceuticals has agreed to pay $272.5

Pharmaceutical

Why hasn’t pharma embraced email marketing?

Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs

How did pharma develop a vaccine so quickly?

IFF, after brief leadership stint under Merck's Frank Clyburn, pawns off pharma solutions business for $2.85B

Pharma is “big business” that uses excuses to keep prices high

Martin Shkreli runs afoul of FTC for potentially skirting lifetime pharmaceutical industry ban

Ferring inks $500M deal with Royalty Pharma on new bladder cancer gene therapy

At long last, AstraZeneca, Pfizer, J&J, Roche and others have an ally in Biden

Scilex's Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect

The current pharma business model is unsustainable

ARS Pharmaceuticals hit with surprise FDA rejection of Neffy, its nasal spray epinephrine alternative

Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case

Discover Breakthrough Pharma Marketing Strategies at Digital Pharma East 2024

FDA rejects Defender Pharma's motion sickness nasal gel candidate

AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players

Delaware's Marlex Pharmaceuticals recalls 2 batches of heart failure drug after labeling mix-up

Supreme Court blocks Purdue Pharma's bankruptcy settlement, threatening immunity to Sackler family

Vanda, despite FDA rejection, swats down another buyout bid from Cycle

Pharma group blasts UK's drug rebate scheme shortly after lauding 'landmark' spending deal

The 2025 Pharma Toolkit for Virtual Medical Education

How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B

As ICER places a spotlight on pharma's price hikes, J&J, Roche and more hit back

Apellis parries Astellas' long-term Izervay data with 3-year results on its rival GA med Syfovre

'The Top Line': Breaking down Eli Lilly’s ESG formula

Addressing the evolving needs of pharma for CDx development

Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

Fierce Pharma Asia—Ono buys Deciphera for $2.4B; Novartis expands PeptiDream collab; WuXi Bio exits BIO 2024

Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis

Eton Pharma hit with FDA rejection for methanol poison treatment as regulator flags manufacturing concerns

Woes mount for Marinus with investor lawsuit, trial failure

Pfizer moves to settle more than 10,000 Zantac cases in state courts: Bloomberg

Harnessing data powers marketing programs to enable precise targeting

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M

Pharma Horizons: Biologics

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency

Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition

How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come

Lilly, AbbVie, BMS and more rally against UK's 'arbitrary' growth cap on branded drug market

In launching epinephrine nasal spray, ARS Pharma has a 'blue sky opportunity,' analyst says

After Xiidra deal with Bausch, Novartis divests Indian eye care brands to J.B. Pharma for $116M

It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash

Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease

Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study

Amneal agrees to $272.5M settlement to resolve opioid lawsuits

Stay Connected